← All trials
NCT04978259
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 24, 2021
- Primary completion
- Feb 28, 2023
- Completion date
- Dec 31, 2023
- First posted
- Jul 27, 2021
- Last posted
- Oct 13, 2021
- Enrollment
- 202
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of SherbrookeLead sponsor
- University of HelsinkiCollaborator
- Kuopio University HospitalCollaborator
- University of TampereCollaborator
- University of SherbrookeReponsible party - principal investigator
- World Health OrganizationCollaborator
- University of OuluCollaborator
- Mikkeli Central HospitalCollaborator
- Seinajoki Central HospitalCollaborator
- University of HelsinkiStudy director
- University of HelsinkiOverall official - principal investigator
- University of HelsinkiCollaborator
- Hyvinkää HospitalCollaborator
- Central Hospital of Kanta-HameCollaborator
- Porvoo HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.